Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Fresh from the Pipeline
  • Published:

Lacosamide

Abstract

In August 2008, lacosamide (Vimpat; UCB), was granted market authorization by the European Commission as an adjunctive therapy for partial-onset seizures with or without secondary generalization in patients with epilepsy. It was approved by the FDA as an adjunctive therapy for partial-onset seizures in October 2008.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. Chang, B. S. & Lowenstein, D. H. Epilepsy. N. Engl. J. Med. 349, 1257–1266 (2003).

    Article  Google Scholar 

  2. Diaz-Arrastia, R. et al. Evolving treatment strategies for epilepsy. JAMA 287, 17–20 (2002).

    Article  Google Scholar 

  3. Perucca, E. et al. Development of new antiepileptic drugs: challenges, incentives, and recent advances. Lancet Neurol. 6, 793–804 (2007).

    Article  CAS  Google Scholar 

  4. Löscher, W. & Schmidt, D. Strategies in antiepileptic drug development: is rational drug design superior to random screening and structural variation? Epilepsy Res. 17, 95–134 (1994).

    Article  Google Scholar 

  5. Cortes, S. et al. Effect of structural modification of the hydantoin ring on anticonvulsant activity. J. Med. Chem. 28, 601–606 (1985).

    Article  CAS  Google Scholar 

  6. Choi, D. et al. Synthesis and anticonvulsant activities of N-benzyl-2-acetamidopropionamide derivatives. J. Med. Chem. 39, 1907–1916 (1996).

    Article  CAS  Google Scholar 

  7. Stöhr, T. et al. Lacosamide, a novel anti-convulsant drug, shows efficacy with a wide safety margin in rodent models for epilepsy. Epilepsy Res. 74, 147–154 (2007).

    Article  Google Scholar 

  8. Beyreuther, B. K. et al. Lacosamide: a review of preclinical properties. CNS Drug Rev. 13, 21–42 (2007).

    Article  CAS  Google Scholar 

  9. European Medicines Agency (EMEA). European Public Assessment Report – Vimpat. EMEA web site [online], (2008).

  10. Food and Drug Administration (FDA). FDA labelling information. FDA web site [online], (2008).

  11. Errington, A. C. et al. The investigational anticonvulsant lacosamide selectively enhances slow inactivation of voltage-gated sodium channels. Mol. Pharmacol. 73, 157–169 (2008).

    Article  CAS  Google Scholar 

  12. Ben-Menachem, E. et al. Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures. Epilepsia 48, 1308–1317 (2007).

    Article  CAS  Google Scholar 

  13. Bialer, M. et al. Progress report on new antiepileptic drugs: a summary of the Eigth Eilat Conference (EILAT VIII). Epilepsy Res. 73, 1–52 (2007).

    Article  Google Scholar 

  14. Chung, S. S. et al. Lacosamide: efficacy and safety as oral adjunctive treatment for partial-onset seizures. Epilepsia 48, 321 (2007).

    Google Scholar 

  15. Perucca, E. Marketed new antiepileptic drugs: are they better than old-generation agents? Ther. Drug Monit. 24, 74–80 (2002).

    Article  Google Scholar 

  16. Rauck, R. L. et al. Lacosamide in painful diabetic peripheral neuropathy: a phase 2 double-blind placebo-controlled study, Clin. J. Pain 23, 150–158 (2007).

    Article  Google Scholar 

  17. IMS MIDAS (2007).

  18. Al-Wakeel, Y. et al. Credit Suisse Equity Research Report (Credit Suisse Securities Europe Ltd, 24 Sep 2008).

  19. Bourdot, B. Deutsche Bank Global Market Research Report on UCB. (Deutsche Bank AG, 8 Jul 2008).

Download references

Author information

Authors and Affiliations

Authors

Ethics declarations

Competing interests

Emilio Perucca has received speaker's or consultancy fees and/or research grants from the manufacturers of carbamazepine and oxcarbazepine (Novartis); carisbamate and topiramate (Johnson & Johnson); eslicarbazepine (BIAL); ethosuximide, gabapentin, phenytoin and pregabalin (Pfizer); lamotrigine (GlaxoSmithKline); lacosamide and levetiracetam (UCB Pharma); retigabine (Valeant); tiagabine, valproic acid and vigabatrin (Sanofi-Aventis); rufinamide and zonisamide (Eisai).

Rights and permissions

Reprints and permissions

About this article

Cite this article

Perucca, E., Yasothan, U., Clincke, G. et al. Lacosamide. Nat Rev Drug Discov 7, 973–974 (2008). https://doi.org/10.1038/nrd2764

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd2764

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing